Skip to main content

Table 4 Association between FGF-23 and cardiovascular disease

From: Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patients

AACscore

Beta

CI

p-value

Model 1. Crude association

0.72

-0.13-1.57

0.10

Model 2. (+ Confounders)*

0.49

-0.35-1.34

0.25

CACscore

Beta

CI

p-value

Model 1. Crude association

0.25

-0.13-0.63

0.20

Model 2. (+Confounders)*

0.001

-0.40-0.40

1.00

LVMI

Beta

CI

p-value

Model 1. Crude association

0.48

-5.79-6.75

0.88

Model 2. (+Confounders)*

-0.70

-7.40-6.00

0.84

LV-dysfunction (LVEF < 45%)

OR

CI

p-value

Model 1. Crude association

0.68

0.40-1.16

0.16

Model 2. (+Confounders)*

0.51

0.26-1.01

0.053

CAD (any vessel occluded)

OR

CI

p-value

Model 1. Crude association

0.94

0.66-0.63

0.20

Model 2. (+Confounders)*

0.65

0.41-1.04

0.08

  1. Beta’s represent changes in LnFGF-23.
  2. AACscore; Abdominal aorta calcification score, CACscore; Coronary artery calcification score, LVMI; Left ventricular mass index, LV-dysfunction; Left ventricular dysfunction. CAD; Coronary artery disease.
  3. Model 1; sKlotho. *Model 2; + age, gender, (ln)dialysis vintage, dialysis type, residual urine production.